ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ashland is considering options, including a sale, for both its composites business and a plant in Marl, Germany, that produces butanediol and derivatives. The composites business has annual sales of about $780 million. The Marl plant employs around 250 people. Ashland says a sale would increase its focus on specialty chemicals. To that end, the firm sold its Valvoline motor oil business last year and acquired the specialty ingredient maker Pharmachem. Ashland considered exiting butanediol in 2016.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X